Testing RC48 and Tislelizumab for recurrent cervical cancer with HER2
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs, RC48 and Tislelizumab, for people with recurrent cervical cancer whose tumors have a protein called HER2. The goal is to see if this treatment can help when previous therapy has stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old and assigned female at birth.
- You have recurrent cervical cancer that has a certain amount of HER2 protein (tested by a biopsy).
- You are able to care for yourself (ECOG score of 0 or 1).
- You have not received chemotherapy or other cancer drugs in the last 4 weeks.
- You have not had another cancer in the past 5 years, except for certain early-stage or skin cancers.
- You are not pregnant and use effective birth control if you could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, RC48, for people with ovarian cancer that came back after responding well to platinum chemotherapy. RC48 targets the HER2 protein on cancer cells, which may stop the tumor from growing. Researchers want to see if it's safe and works better than current options.
This trial tests a combination of two targeted drugs (RC48 and QL1706) for people with cervical cancer that has returned after initial treatment. It focuses on cancers that have a protein called HER2.
This trial tests a combination of two drugs (nimotuzumab and tislelizumab) plus radiation for women whose cervical cancer has come back or spread to a few places in the body. The goal is to see if this treatment can shrink tumors and help patients live longer.
This trial tests whether adding tislelizumab to standard chemotherapy and radiation works better as first treatment for stage IIIC2 cervical cancer. It aims to improve how well the cancer responds and controls the disease.
This Phase 2 study tests a combination of anti-cancer drugs for HER2-positive or HER2-mutated advanced colorectal (bowel) cancer after standard treatment has failed or you couldn’t tolerate it. It aims to see if this treatment can better control the cancer and shrink tumors.
This trial tests a combination of three drugs—RC48 (a targeted therapy), sintilimab (an immunotherapy), and S-1 (a chemotherapy pill)—as a first treatment for advanced HER2-positive stomach cancer that has not been treated before. The goal is to see if this triple therapy works better than current options.
Hear when a new Cervical Cancer Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.